NBIX
Neurocrine Biosciences
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: NBIX
- PEG Ratio
Based on the most recent data from Aug 1, 2026, NBIX's PEG ratio comes in at 0.23. This metric factors in a PE of 23.66 with an earnings growth rate of 102.6%. Relative to the 0.97 average from the previous four quarters, the PEG ratio has plunged by 76%.
NBIX PEG ratio history
Looking at the last eight years, NBIX's PEG ratio has has been around 2.3 on average. At 0.23, today's PE to growth ratio sits 90% below its historical average. Within the last eight years, the Jun 2025 quarter recorded the highest PEG value at 24.08. At 0.02, the Dec 2020 quarter showed the minimum PEG ratio in this period.
Neurocrine Biosciences PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.71 | 29.49 | 41.5% |
| 2024 | 1.22 | 40.15 | 32.8% |
| 2023 | 0.87 | 51.47 | 59% |
| 2022 | 1.07 | 74.19 | 69.5% |
| 2021 | N/A | 89.65 | -78.3% |
| 2020 | 0.02 | 21.88 | 995% |
| 2019 | 3.64 | 268.73 | 73.9% |
| 2018 | 2.72 | 310.48 | 114.2% |
| 2017 | N/A | N/A | 0.6% |
| 2016 | N/A | N/A | -55.2% |
| 2015 | N/A | N/A | -29.6% |
| 2014 | N/A | N/A | -17.4% |
| 2013 | N/A | N/A | -962.5% |
| 2012 | N/A | 93.5 | -88.2% |
| 2011 | 0.02 | 12.5 | 553.3% |
Neurocrine Biosciences PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 0.23 | 23.91 | 102.6% |
| Mar 2026 | 0.16 | 19.63 | 121.5% |
| Dec 2025 | 0.71 | 29.49 | 41.5% |
| Sep 2025 | 2.78 | 32.57 | 11.7% |
| Jun 2025 | 24.08 | 36.12 | 1.5% |
| Mar 2025 | N/A | 36.5 | -19.6% |
| Dec 2024 | 1.22 | 40.15 | 32.8% |
| Sep 2024 | 0.31 | 29.85 | 96.9% |
| Jun 2024 | 0.46 | 40.14 | 87.4% |
| Mar 2024 | 0.08 | 36.58 | 462.7% |
| Dec 2023 | 0.87 | 51.47 | 59% |
| Sep 2023 | 0.26 | 57.4 | 221.3% |
| Jun 2023 | 0.04 | 51.53 | 1,307.7% |
| Mar 2023 | N/A | 151.07 | -11.8% |
| Dec 2022 | 1.07 | 74.19 | 69.5% |
NBIX average PEG ratio chart
Measured against past performance, NBIX's PEG ratio is below the 3, 5 and 10-year averages.
PEG comparison
Neurocrine Biosciences's PEG of 0.23 is below the Healthcare sector and the industry average. Compared to its Healthcare sector average of 0.56, Neurocrine Biosciences's PEG is 59% lower.
NBIX EPS growth
NBIX Price vs fair value
NBIX PEG vs peers
Compared to its peers, NBIX has a PEG ratio under stocks LLY and RGEN, while above ANIP's.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| ANIP Ani Pharmaceuticals Inc | 0.05 | $1.8B |
| NBIX Neurocrine Biosciences Inc | 0.23 | $17.23B |
| LLY Lilly(Eli) & Company | 0.31 | $1.06T |
| RGEN Repligen Corp | 0.5 | $8.18B |
| RPRX Royalty Pharma plc - Class A | N/A | $33.03B |
| ABBV Abbvie Inc | N/A | $434.75B |
| PFE Pfizer Inc | N/A | $142.37B |
Frequently asked questions
What is Neurocrine Biosciences's PEG ratio?
According to Aug 1, 2026 data, NBIX's PEG ratio sits at 0.23.
What is the 3-year average PEG ratio for Neurocrine Biosciences (NBIX)?
NBIX's 3-year PEG ratio average stands at 2.83.
What is the 5-year average PEG ratio for Neurocrine Biosciences (NBIX)?
NBIX's 5-year PEG ratio average stands at 2.31.
What is the highest PEG ratio for NBIX?
NBIX's PEG ratio peaked at 24.08 during the Jun 2025 quarter - the highest in eight years.
How does the current PEG ratio for NBIX compare to its historical average?
NBIX currently has a PEG ratio 90% below its 8-year average.
Why is Neurocrine Biosciences's PEG ratio so low?
Rapid earnings growth combined with a reasonable valuation yields NBIX a PEG ratio of 0.23.
How is NBIX's PEG ratio calculated (Neurocrine Biosciences PEG ratio formula)?
PEG equals PE divided by EPS growth (YoY TTM). As of Aug 1, 2026, Neurocrine Biosciences has a P/E ratio of 23.66. Earnings grew at 102.6% over the TTM period ending Jun 2026. Applying the formula, this produces a price to earnings growth ratio of 0.23. PEG RATIO(0.23) = PE RATIO(23.66) / EPS GROWTH(102.6%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.